DOCSLIB.ORG

Can You Prevent Prostate Cancer? INSIDE Consumer Education: a High-Fat, Western This Year More Than Move to the U.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Can You Prevent Prostate Cancer? INSIDE Consumer Education: a High-Fat, Western This Year More Than Move to the U.S Can You Prevent Prostate Cancer? INSIDE Consumer Education: A high-fat, Western This year more than move to the U.S. and Food News You Can Use 67 230,000 men in the adopt a more Western- diet, rich in animal U.S. will be diagnosed style lifestyle. This Recipes: with prostate cancer means that genetic fac- Fast Weekday Meals 68 products may not and more than 30,000 tors are unlikely to ex- will likely die from it. plain the very low rates Handout: only be promoting Holiday Substitutions This makes it the most of prostate cancer mor- 69 atherosclerosis, but common cancer in men, tality in Asian and Handout: as well as the number African countries. Cholesterol Quiz may also be promot- one cause of cancer 70 death in non-smoking Lowering Cholesterol ing the growth and men. The death rate Levels Reduces For Professionals: Cancer Risk Educators’ Idea File: from prostate cancer in Hot Topics spread of prostate the U.S. is 5 to 10 times Back in the 1970s, a 71 higher than it is in study in Hawaii found cancer and likely Dr. Jay’s Review: many developing coun- that smokers with high- Pain Killers and HTN er serum cholesterol 72 other cancers as well. tries in Asia or Africa. Even in Japan, the levels had a much high- Supplement: death rate from prostate er risk of developing Online Password cancer remains far low- lung cancer. In May Subscriber Benefits er than in the U.S., al- 2005, a study of nearly Back Issue Highlights though it is rising as a half million U.S. vet- they adopt a more erans was presented at NEXT ISSUE: Western-style lifestyle. the American Society of Recipes: Food Gifts However, African- Clinical Oncology. The Holidays with MyPyramid Americans in the U.S. results showed that the More Hot Topics have the highest death development of lung, rate from prostate can- prostate, pancreatic and cer, and Asian-Ameri- esophageal cancers was cans appear to quickly cut by about 50% in lose their resistance to those taking statin the disease when they drugs to lower their Continued on page 66 SEPTEMBER 2005 Continued from front page minutes a day, 6 days a inclusion of small prostate and other can- week and underwent stress amounts of fish and ani- cers in people consuming cholesterol levels. This management techniques. mal protein but without diets high in saturated fat data suggests a high-fat, The control subjects supplements. In this and cholesterol. Western diet rich in ani- were instructed to follow study, the serum of the mal products may not standard medical advice. participants before they Bottom Line: only be promoting ather- PSA levels fell mod- started the study served Very-low-fat, near-vege- osclerosis, but may also estly after one year in the as the control. The exper- tarian diets markedly be promoting the growth experimental group but iment serum was after lower serum cholesterol and spread of prostate rose modestly in the con- they had been on the pro- levels and appear to cancer and likely other trol subjects. This same gram for a few weeks.2 regress atherosclerotic le- cancers as well. study, conducted by Dr. Serum cholesterol fell sions in most people. Ornish and others, also 20-30% on both the Or- Since most men who de- Lifestyle Shown to reported that the growth nish and Pritikin diets. velop prostate cancer ac- Slow Progression of of a line of prostate can- It appears that a very- tually die from athero- Prostate Cancer cer cells (LNCaP) was low-fat, near-vegetarian sclerotic disease, it seems In the September issue of markedly inhibited in diet is likely to slow the reasonable to encourage the Journal of Urology, a those in the experimental progression of prostate men with early prostate study of men with early group, compared to those cancer, at least in part be- cancer to adopt a very- prostate cancer proven who received conven- cause it lowers serum low-fat, near-vegetarian by biopsy and PSA tional medical treatment.1 cholesterol levels. Grow- diet. They should also be scores (ranging from 4- In 2001, a study at the ing evidence suggests encouraged to get a little 10ng/ml) were randomly Pritikin Longevity Center that higher cholesterol sunshine several days a assigned to one of two reported similar marked levels in cell membranes week, as low levels of vi- groups. inhibition of the growth can interfere with chemi- tamin D also appear to The experimental, inten- of prostate cancer cells cal signals for abnormal promote prostate cancer. sive lifestyle change group grown in the serum of cells to self-destruct. By James J. Kenney, was placed on a very-low- people who had followed This may promote the PhD, RD, FACN. fat vegan diet supplement- the Pritikin program for growth and spread of ed with fish oil, vitamin E, just a few weeks. The cancer cells in the body References: selenium and vitamin C. In diet was similar to Or- and help explain the 1 J Urol. 2005;174:1065 addition, they walked 30 nish study except for the much higher rate of 2 J Urol. 2001;166:1185 How do I avoid getting cancer? 1. Get enough vitamin D from sunshine or skim milk; this means 5-10 minutes of strong sun several times a week or 4 servings of skim milk plus two servings of fatty fish each week. (CFFH 05/01) 2. Eat more fruits and vegetables. 3. Consume more whole grains, like whole wheat pasta, brown rice, high-fiber cereal, oats, barley, etc. 4. Choose fat-free or low-fat dairy products. 5. Cut down on meat consumption; add fish, beans and nuts to your diet. 6. Drink alcohol only in moderation. 7. If you smoke, you should quit. 8. Exercise on a regular basis, about 60 minutes a day, most days of the week. 9. Lower the amount of sodium in your diet by consuming more fresh foods. ? 10. Maintain a healthy body weight. If people in the U.S. would follow better diet strategies, they could cut the number of cancer deaths even more than by eliminating smoking alone. If they followed all of these strategies, the death rate from cancer would likely fall 70-80% during the next 2 decades! – J.K. 66 Communicating Food for Health September 2005 Food News You Can Use Chocolate news ters, an ingredient de- A study published by rived from natural plant the American Heart As- sources, proven to sig- sociation showed that nificantly reduce cho- people who ate a spe- lesterol levels. cial flavonoid-enriched Ingredients: Sugar, dark chocolate had a Corn Syrup, Plant small transient decrease Stanol Esters, Nonfat in blood pressure. Of Milk, Cocoa Powder, course this has prompt- Less than 2% of Salt, Fast food doesn’t a plain hamburgers ed a media statement Soy Lecithin, Mono- have to be junk food are usually small and that chocolate lowers and Diglycerides, Invert Here are some recent inexpensive. While blood pressure. By far, Sugar and Flavors. “better finds” from they are not always most Americans need to Per 1 chew: 20 calo- popular fast food low in sodium they be more concerned with ries, 4 g carbohydrate, 3 restaurants. are usually lower in lowering the salt in g sugars, 15 mg sodium, • McDonald’s is offer- calories than adult- their diets and with in- .85 g plant stanol esters. ing Apple Dippers. sized meals and sand- creasing their consump- Consuming 4 serv- We recently tried wiches. tion of fruits, vegeta- ings per day of Benecol them and found them bles, whole grains and Products will provide to be a good fast treat. Light juice not 100% low-fat dairy products the 3.4 grams of plant They are a much bet- juice than with eating choco- stanol esters (2.0 grams ter choice than French Light orange juice and late. Salt in most peo- Plant Stanols) recom- fries and come in a other juices that are ple’s diets comes from mended by the National handy bag. touted as light or lower processed foods and Cholesterol Education • McDonald’s also of- in calories are often restaurant meals. Program. fers yogurt and fruit lower in real juice, too. Chocolate is very high Benecol Spreads without granola (130 We recently took a look in fat and calories. have been reformulated calories), fruit and at these products, which Consider that most so that one tablespoon walnut salad (310 are sold with the orange chocolate candy bars contains 0.85 grams of calories), side salad juice in the grocery are well over 250 calo- plant stanol esters (15 calories) and a re- store. For example, ries for a very small which is the same duced-fat vanilla ice Minute Maid Light Or- portion. amount contained in cream cone (150 calo- ange Juice Beverage one Benecol Smart ries) for calorie con- contains 50 calories and Benecol candy and Chew (the amount was scious diners. 10 grams of sugar per 8 spread news formerly 1.7 grams per • Salad without dress- fl. oz. serving (vs. 110 Benecol Smart Chews, tablespoon). This facili- ing or with dressing calories and 24 grams a new candy from the tates the 4-a-day cam- on the side is usually of sugar per 8 fl. oz. maker of Benecol paign from Benecol. a good choice. Just serving of 100% orange spread, are available in Benecol is trans fat beware of fried chick- juice) but it is only creamy caramel and free. en and cheese addi- 42% juice.
Load more

Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • 2Nd Quarter 2015 Earnings Call Presentation
    2nd Quarter 2015 Earnings Call Presentation July 14, 2015 1 Louise Mehrotra Vice President Investor Relations 2 Note on Forward-Looking Statements These presentations contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health
    [Show full text]
  • Approved Prenatal Medications Pain Medications • Tylenol
    Approved Prenatal Medications Pain Medications Tylenol (acetaminophen) for minor aches and pains, headaches. (Do not use: Aspirin, Motrin, Advil, Aleve, Ibuprofen.) Coughs/Colds Robitussin (Cough) Robitussin DM (non-productive cough) DO NOT USE TILL OVER 12 WEEKS Secrets and Vicks Throat Lozenges Mucinex Sore Throat Chloraseptic spray Saline Gargle Sucrets and Vicks Throat Lozenges Antihistamines/Allergies Zyrtec Claritin Benadryl Dimetapp Insomnia Benadryl Unison Hemorrhoids Preparation H Tucks Anusol Diarrhea Imodium (1-2 doses- if it persists please notify the office) BRAT diet (bananas, rice, applesauce, toast) Lice RID (only!) DO NOT USE Kwell Itching Benadryl Calamine or Caladryl Lotion Hydrocortisone cream Heartburn, Indigestion, Gas Tums Gas-X Mylanta Pepcid Maalox Zantac *DO NOT USE PEPTO BISMOL- it contains aspirin Decongestants Sudafed Robitussin CF- Only if over 12 weeks Tavist D Ocean Mist Nasal Spray (saline solutions) Nausea Small Frequent Meals Ginger Ale Vitamin B6 Sea Bands Yeast Infections Monistat Mycolog Gyne-lotrimin Toothache Orajel May see dentists, have cavity filled using Novocain or lidocaine, have x-rays with double lead shield, may have antibiotics in the Penicillin family (penicillin, amoxicillin) Sweetners- all should be consumed in moderation with water being consumed more frequently Nutrisweet (aspartame) Equal (aspartame) Splenda (sucralose) Sweet’n Low (saccharin) *note avoid aspartame if you have phenylketonuria (PKU) Constipation Colace Fibercon Citrucel Senokot Metamucil Milk of Magnesia Fiberall Miralax Eczema Hydrocortisone Cream Medications to AVOID Accurate Lithium Paxil Ciprofloxacin Tetracycline Coumadin Other Chemicals to AVOID Cigarettes Alcohol Recreational Drugs: marijuana, cocaine, ecstasy, heroin .
    [Show full text]
  • Page 1 of 27 MD Consult: Diabetes, Diet For: Comprehensive Version
    MD Consult: Diabetes, Diet for: Comprehensive Version: Patient Education Page 1 of 27 Boise Kidney and Hypertension 3525 East Louise Rd Ste 100 Meridian, ID 83642 208-846-8335 Diabetes diet Highlights Lifestyle Changes Essential for People at Risk for Diabetes Lifestyle interventions that include weight loss, dietary changes, and increased physical activity can definitely help prevent or delay the progression to diabetes among at-risk people, suggest several recent studies. Weight loss through diet and exercise is especially important for overweight people with pre-diabetes. Grain Fiber Important for Diabetes Prevention Eating whole-grain, fiber-rich, cereal foods may help reduce the risk of developing type 2 diabetes, indicates a 2007 study in the Archives of Internal Medicine. In the study, people who consumed the most fiber from grains and cereals had a 33% lower risk of developing diabetes than people with the lowest fiber intakes. The study also found an association between high magnesium intake and reduced diabetes risk. Although fruits and vegetables also contain fiber, they did not appear to affect diabetes risk. Low-Fat Dairy Products Incorporating low-fat dairy products (such as yogurt and milk) into a healthy diet may help reduce diabetes risk for women, suggests a study in Diabetes Care. Beware of Internet Dietary Supplement Scams In 2006, the FDA alerted consumers not to be misled by dietary supplements advertised on the Internet as treatments or cures for diabetes. These products have not been scientifically studied or approved. Low-Glycemic Index Diets Food low on the glycemic index -- such as whole grains, fruits, lentils, and soybeans -- can help promote weight loss and heart health.
    [Show full text]
  • ODWB 16 0.Pdf
    PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Thursday, Kathleen Elliott, Pediatrics/Geriatrics – Take 42824 July 21, OD Your Pick (2 hrs) 2 hours 2016 GO Implications of Selected Corneal Jeffrey Urness, 49516 2 hours Conditions on Refractive Surgery OD (2 hrs) AS Therapeutic Environment, Diet and Amber Giannoni, Supplements: What Role Do 40852 1 hour OD They Play in Dry Eye Disease? (1 hr) AS Therapeutic Friday, Amber Giannoni, Dry Eye and Systemic Disease 40851 2 hours July 22 OD (2 hrs) SD Therapeutic 49515 Kathleen Elliott, The ABC’s of Pediatric Eye Care 1 hour OD (1 hr) FV John McGreal, New Ideas in Glaucoma 43612 2 hours OD Management (2 hrs) GL Therapeutic Total hours offered: 10 Total hours earned: Name License # Mailing Address ______ Please retain a copy of this stamped form as verification of hours earned. Please be advised that your individual state board makes the final determination of applicable hours. For more information, contact Pacific University College of Optometry, 2043 College Way . Forest Grove, OR 97116 . 503-352-2202 1 of 193 2 of 193 PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Saturday, John McGreal, The Latest Trends in 43497 2 hours July23 OD Contemporary Medicine (2 hrs) PH Therapeutic Non-Surgical Radiofrequency Kathleen Elliott, 46927 2 hours Periocular Soft Tissue OD Rejuvenation (2 hrs) AS Therapeutic 42998 John McGreal, New Tools for the Tool Box 1 hour OD (1 hr) GO Sunday, Jeffrey Urness, 49517 1 hour Bacterial Corneal Ulcers (1 hr) July 24 OD AS Therapeutic 49514 Kathleen Elliott, Pediatric Case Reports: The 1 hour OD Good, Bad and Ugly (1 hr) FV 43552 Amber Giannoni, Setting Up a Dry Eye Practice 1 hour OD (1 hr) PM Jeffrey Urness, Corneal Transplantation Front 40409 2 hours OD to Back, Side to Side.
    [Show full text]
  • Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive
    Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive, Braintree, Essex, CM77 8YG Telephone E-mail Website 01245 362500 [email protected] www.pursuitgroup.co.uk Candidate: 24870 2000 - 2003 South Bank University – • BA (Hons) Business Administration (2:1) 1998 - 2000 Westcliff High School Education: • A-levels: Biology, General Studies, Psychology 1993 - 1998 St. Bernard’s High School • GCSE’s: 10 A-C subjects, including English, Mathematics and Sciences Notice Period: 2 months Salary £38,000 NB: To give you an enhanced understanding of the candidate we have checked the validity of the information and left the CV in its original format. A media marketing manager with 10+ years’ experience delivering multiple cross-media campaigns for high profile brands. With track record of executing communication strategies and client objectives from conception to completion. Employment History: Media Account Director Nov 16 – present • Manage and coordinate a team to create and develop Nestlé’s Water and Nutrition divisions’ annual marketing strategy • in line with business objectives • Utilise a mix of media channels including above and below the line media (TV, OOH, print, radio, digital, social and • product placements) ensuring relevancy to the target audience • Keep up to date with new media innovations, changing media landscape and trends in the industry • Develop consumer and shopper insights to feed into overall media strategy to present back to senior business leaders • Strategise and implement
    [Show full text]
  • Creative Director 561.714.1585 Andy Mathurin
    Hello, I am: Looking for role as: Let’s Connect: Andy Mathurin Creative Director 561.714.1585 Associate Creative Director, [email protected] Brand Strategist New York What I do: PROFILE Brand Strategy Over 8 years leading branding and marketing concepts with career spanning 360 campaigns, broadcast, print, OOH, social, digital, video and experiential Identity Design across major worldwide brands. Energetic and a creative visionary offering Storytelling demonstrated expertise in all aspects of branding and strategy, with core focus Thought Leader on delivering business results. Team Builder Marketing WINS Project Management Successes have included winning several accounts for new business, resulting in agency being awarded Global Agency of the Year by AdAge & Adweek. Toolkit: AOR: Havas - Vascepa 2019, Havas - Alcon 2019, J3 - OGX 2018, UM - H&M 2017, UM - Sony 2017, BMW 2016, UM - Coca Cola 2016 Sketch XD Microsoft Office PROFESSIONAL EXPERIENCE Avocode 03.18 HAVAS | Manhattan, NY Photoshop Present Associate Creative Director Strategic partner, focusing on brand equity for healthcare and InDesign pharmaceutical brands. Responsible for new business and leading creative Illustration team/studio across all digital platforms (specializing in social). After Effects Brands include: Zicam, Alcon, GSK, NUCALA, TRELEGY, & ANORO. 09.14 Universal McCann Worldwide | Manhattan, NY 03.18 Personality: Associate Creative Director + Senior Art Director Hands-on leader in identity design. Champion participant in winning new Human business pitches. Guiding and advising clients on high-level executions. Confident Brands include: Sony Pictures, GoPro, McCormick, BMW... and more. Effective Communicator - Demonstrate strong leadership overseeing staff in the day-to-day projects Motivational Honest with Integrity - Deliver against demanding brand objectives and develop creative that Empathetic exceeds business needs, managing projects from concept through completion: timelines, budgets, schedules, etc.
    [Show full text]
  • Challenges Facing the Branded Drug Industry
    CHAPTER 1 Challenges Facing the Branded Drug Industry In 2004, Capgemini conducted an industry - wide survey on pharmaceutical lifecycle management (LCM) ( “ Increasing the lifetime value of pharmaceuti- cal products, ” Capgemini Vision & Reality Research, 2004). They held a series of interviews with pharmaceutical industry executives, asking them how important LCM had been for their business in the past 5 years and how they expected its importance to change during the coming 5 years. As can be seen in Figure 1.1 , these executives felt that LCM had been important, but 90% predicted that its importance would grow during the 5 years following the publication of the report (2006 – 2010), with 60% expecting it to become much more important. Today, just after the time horizon of this prediction, we can look back and state that it has proven to be very accurate, with more and more attention paid to LCM in company statements, conferences, and industry reports. Why did these executives expect LCM to gain in importance, and why has their prediction proven to be correct? To set the scene for any discussion of LCM of pharmaceuticals, it is essential that one fully understands the challenges facing the branded drug industry. On the one hand, many of these factors are drivers of the increased interest in LCM; on the other hand, some of the factors actively discourage LCM and put into question the sustainability of certain LCM strategies that were suc- cessful in the past. As we see it, the main challenges are the following: • Depleted COPYRIGHTEDnew molecular entity (NME) pipelines/lower MATERIAL R & D effi ciency • Higher development costs • Safety concerns • Tougher environment for pricing, reimbursement, and listing Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand, First Edition.
    [Show full text]
  • Bowling V. Johnson & Johnson, Et
    Case 1:17-cv-03982-AJN Document 1 Filed 05/25/17 Page 1 of 21 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SUZANNA BOWLING, individually and on behalf of all others similarly situated, CASE NO. Plaintiff, v. CLASS ACTION COMPLAINT JOHNSON & JOHNSON and McNEIL NUTRITIONALS, LLC, JURY TRIAL DEMANDED Defendants. Plaintiff Suzanna Bowling brings this action on behalf of herself and all others similarly situated against Defendants Johnson & Johnson and McNeil Nutritionals, LLC (“McNeil”) (collectively, “J&J” or “Defendants”). Plaintiff makes the following allegations pursuant to the investigation of her counsel and based upon information and belief, except as to the allegations specifically pertaining to herself, which are based on personal knowledge. NATURE OF THE ACTION 1. This is a class action lawsuit regarding Defendants’ false and misleading labeling of Benecol Regular and Light Spreads (together, “Benecol Spreads”), each of which uniformly claims that the product (i) contains “No Trans Fats” and “No Trans Fatty Acids,” and (ii) is generally recognized as safe for human consumption (the “Misrepresentations”). However, Benecol Spreads contain trans fat through the use of partially hydrogenated oils. Thus, the labels on Benecol Spreads are false and misleading. Case 1:17-cv-03982-AJN Document 1 Filed 05/25/17 Page 2 of 21 2. In June 2015, the FDA concluded that partially hydrogenated oils – the same oils found in Benecol Spreads – are not “generally recognized as safe” for use in human food due to “an increased risk of coronary heart disease by contributing to the buildup of plaque inside the arteries that may cause a heart attack.” Thus, Benecol Spreads are not generally recognized as safe for human consumption.
    [Show full text]
  • Johnson & Johnson 1999 Third Quarter Sales Increased 17.9% Net
    Johnson & Johnson 1999 Third Quarter Sales Increased 17.9% Net Earnings Rose 14.4% EPS Rose 14.3 NEW BRUNSWICK, N.J., Oct. 19-- Johnson & Johnson (NYSE: JNJ) today announced sales of $6.7 billion and net earnings of $1.1 billion for the third quarter of 1999, increases of 17.9% and 14.4%, respectively, over 1998 third-quarter results. Diluted earnings per share for the third quarter were $.80, up 14.3% from the same period in 1998. The impact of the stronger dollar relative to foreign currencies decreased third-quarter sales by 1.3%. Domestic sales were up 24.1%, while international sales increased 10.7%, reflecting a negative currency impact of 2.9%. "We continue to achieve strong double-digit sales and earnings growth that reflects the strength and vitality of our businesses in all segments and almost all geographic areas," said Ralph S. Larsen, Chairman and Chief Executive Officer. "Of particular note is the impressive performance of our domestic pharmaceutical business." Worldwide pharmaceutical sales of $2.6 billion for the quarter increased 23.9% over the same period in 1998, including 35.7% growth in domestic sales and a 9.5% increase in international sales. International sales gains of 12.6% in local currency were offset by a negative currency impact of 3.1%. Sales growth reflects the strong performance of PROCRIT/EPREX, for the treatment of anemia; RISPERDAL, an antipsychotic medication; DURAGESIC, a transdermal patch for chronic pain; LEVAQUIN, an anti-infective; ULTRAM, an analgesic, and the oral contraceptive line of products. During the quarter, the company announced a $4.9 billion definitive stock-for-stock merger with Centocor, Inc., a leader in monoclonal antibody technology and acute vascular care and immunology products.
    [Show full text]
  • 2014 Annual Report • 1 Management’S Discussion and Analysis of Results of Operations and Financial Condition
    ANNUAL REPORT 2014 MARCH 2015 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer I am often asked what led me to work in Perhaps there’s no better proof of that than the THERE IS health care and why I chose to spend most success Johnson & Johnson achieved in 2014. NO COMPANY of my career at Johnson & Johnson. From my We delivered solid financial results, with full-year BETTER first job at Janssen, the flagship company of 2014 sales of $74.3 billion and adjusted net POSITIONED our Pharmaceutical segment, to my current earnings of $17.1 billion†, while also continuing TO HELP MEET role as the company’s Chairman and CEO to make investments to accelerate growth for THESE URGENT 25 years later, the answer always begins the long term. NEEDS THAN with Our Credo. JOHNSON & And while I am pleased with our performance, JOHNSON A simple yet powerful document penned we know that we can never rest, because by General Robert Wood Johnson, the son of providing sustainable high-quality health care our founder and our company’s first Chairman, is one of our society’s greatest challenges. Our Credo outlines the Company’s commitments and responsibilities to the people and This is an unprecedented era in human history. communities we touch every day with our The historic aging rate of the world’s population, products and services. For more than 70 years along with a growing middle class around the now, it has served as the moral compass of world, brings dramatically greater demand for Johnson & Johnson – ensuring we never lose higher quality health care; and governments sight of our strong values and the important and health systems must manage this with needs of the many stakeholders we serve.
    [Show full text]
  • Ronald Monk, Et Al. V. Johnson & Johnson, Et Al. 10-CV-04841
    James E. Cecchi D. Seamus Kaskela Lindsey H. Taylor David M. Promisloff CARELLA, BYRNE, CECCHI, BARROWAY TOPAZ KESSLER OLSTEIN, BRODY & AGNELLO, P.C. MELTZER & CHECK, LLP 5 Becker Farm Road 280 King of Prussia Road Roseland, New Jersey 07068 Radnor, Pennsylvania 19087 (973) 994-1700 (610) 667-7706 Ramzi Abadou Erik D. Peterson Stacey Kaplan BARROWAY TOPAZ KESSLER MELTZER & CHECK, LLP 580 California Street, Suite 1750 San Francisco, California 94104 (415) 400-3000 Attorneys for Plaintiff UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY Civil Action No. RONALD MONK, Individually and on Behalf of All Others Similarly Situated, Plaintiff, vs. COMPLAINT and DEMAND FOR JURY TRIAL JOHNSON & JOHNSON, WILLIAM C. WELDON, DOMINIC J. CARUSO and PETER LUTHER, Defendants. Plaintiff Ronald Monk, individually and on behalf of others similarly situated, by way of Complaint against Johnson & Johnson, William C. Weldon, Dominic J. Caruso, and Peter Luther, say: INTRODUCTION AND OVERVIEW 1. This is a class action for violations of the anti-fraud provisions of the federal securities laws on behalf of all purchasers of Johnson & Johnson (“JNJ” or the “Company”) publicly traded securities between October 14, 2008 and July 21, 2010 (the “Class Period”), who were damaged thereby. 2. JNJ is a healthcare company that sells, among other things, over-the-counter (“OTC”) drugs to consumers. During the Class Period, defendants repeatedly touted the success and revenue of OTC drug sales by its subsidiary McNeil-PPC, Inc. (“McNeil”). At the same time, defendants failed to disclose that a number of manufacturing facilities were failing to maintain current good manufacturing practices (“cGMPs”).
    [Show full text]